Management of diabetic nephropathy

Journal of the Royal Society of Medicine

Volumn 94, Issue 5, 2001, Pages 210-217

  Foggensteiner, Lukas ^a   Mulroy, Sharon ^a   Firth, John ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIDIABETIC AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; GENETIC PREDISPOSITION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; LABORATORY DIAGNOSIS; MICROALBUMINURIA; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PROTEIN RESTRICTION; REVIEW; RISK FACTOR; SMOKING CESSATION; ULTRAFILTRATION;

EID: 0035018099     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1177/014107680109400504     Document Type: Review

References (69)

1. 1 Kimmelstiel P , Wilson C. Intracapillary lesions in the glomeruli in the kidney. Am J Pathol 1936;12:83-97
2. 2 Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999;42:263-85
3. 3 Mogensen CE, Andersen MJ. Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment. Diabetologia 1975;11:221-4
4. 4 Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy - an 8-year prospective study. Kidney Int 1992;41:822-8
5. 5 Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72:375-80
6. 6 Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-60.
7. 7 Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Makmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;i:1430-2
8. 8 Dinncen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997;157:1413-18.
9. 9 Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int 2000;58:302-11
10. 10 Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501
11. 11 Ballard DJ, Humphrey LL, Melton LJ 3rd, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 1988;37:405-12
12. 12 Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309-17
13. 13 Hasslacher C, Stech W, Wahl P, Ritz, E. Blood pressure and metabolic control as risk factors for nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 1985;28:6-11
14. 14 Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P. Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36: 1051-6
15. 15 Rossing P, Hommel E, Smidt UM, Parving HH. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993;42:715-19
16. 16 Mogensen CE. Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J Intern Med 1994; 233:297
17. 17 Microalbuminuria Collaborative Study Group, UK. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ 1993;306:1235-9
18. 18 Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-19
19. 19 Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? [Editorial]. Kidney Int 1990;38:384-94
20. 20 Yoshida H, Kuriyama S, Atsumi Y, et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 1996;50:657-64
21. 21 Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia - a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994;45:S125-31
22. 22 Yokoyama H, Tomonaga O, Hirayarna M, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997;40:405-11
23. 23 Halimi JM, Mimran A. Renal effects of smoking: potential mechanisms and perspectives. Nephrol Dial Transplant 2000;15:938-40
24. 24 Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985;78:785-94
25. 25 Marshall SM, Alberti KG. Screening for early diabetic nephropathy. Ann Clin Biochem 1986;23(Pt 2):195-7
26. 26 Gatling W, Knight C, Hill RD. Screening for early diabetic nephropathy: which sample to detect microalbuminuria? Diabet Med 1985;2:451-5
27. 27 American Diabetes Association Clinical practice recommendations 2000. Diabetes Care 2000;23(suppl 1):S1-116
28. 28 Mogensen CE. Management of early nephropathy in diabetic patients. Annu Rev Med 1995;46:79-93
29. 29 Cockroft D, Gault MK. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
30. 30 Olsen S, Mogensen CE. How often is NIDDM complicated with nondiabetic renal disease? An analysis of renal biopsies and the literature. Diabetologia 1996;39:1638-45
31. 31 Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982;285:685-8
32. 32 Parving HH, Smidt UM, Hommel E, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993;22:188-95
33. 33 Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987;294:1443-7
34. 34 Parving HH, Hommel E. Prognosis in diabetic nephropathy. BMJ 1989;299:230-3
35. 35 Melbourne Diabetic Nephropathy Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991;302:210-16
36. 36 Christensen CK, Mogensen CE. Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 1985; 7:11109-13
37. 37 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13
38. 38 Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62
39. 39 Ramsay LE, Williams B, Johnston GD, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999;319:630-5
40. 40 Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. BMJ 2000;320:705-8
41. 41 JNC. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46
42. 42 Tuomilehto J, Rustenyte D, Birkkenhayer WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999;340:677-84
43. 43 Viberti GC, Laffel L, Gans DJ. Secondary prevention of diabetic nephropathy by captopril in patients with insulin-dependent diabetes-mellitus (IDDM) and microalbuminuria. J Am Soc Nephrol 1994
44. 44 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62
45. 45 EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92
46. 46 Ravid M, Savin H, Jutrin I, Bental T, Lang R, Lishner M. Long-term effect of ACE inhibition on development of nephropathy in diabetes mellitus type II. Kidney Int Suppl 1994;45:S161-4
47. 47 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9
48. 48 Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst Rev 2000;2
49. 49 Reichard P, Pihl M, Rosenquist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996;39:1483-8
50. 50 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1985;352:837-53
51. 51 Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
52. 52 Microalbuminuria Collaborative Study Group, United Kingdom. Intensive therapy and progression to clinical albumimuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995;311:973-7
53. 53 Muntner P, Coresh J, Smith JC, Echfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000;58:293-301
54. 54 Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12:1908-15
55. 55 Maschio G, Oldrizzi L, Rugiu C, De Biase V, Loschiavo C. Effect of dietary manipulation on the lipid abnormalities in patients with chronic renal failure. Kidney Int Suppl 1999;31:S70-2
56. 56 West KM, Ahuja MM, Bennett PH, et al. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care 1983;6:361-9
57. 57 Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16: 434-44
58. 58 Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32: 300-4
59. 59 Haffner SM. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care 1997;20:469-71
60. 60 Pfeffer MA, Sacks RM, Moyle LA, et al. Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995;76:98C-106C
61. 61 Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98:2513-19
62. 62 Koskinen P, Manttari M, Manninen V, Huttunenctk, Heinnonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15:820-5
63. 63 Shephard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333:1301-7
64. 64 Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988;260:3456-60
65. 65 Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis [see comments]. Ann Intern Med 1996;124:627-32
66. 66 Waugh NR, Robertson AM. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2000;2
67. 67 Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308;81-106
68. 68 Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41
69. 69 Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35